-

Benson Hill Announces Third Quarter Earnings Release Date

original

ST. LOUIS--(BUSINESS WIRE)--Benson Hill, Inc. (Nasdaq: BHIL, the “Company” or “Benson Hill”), a seed innovation company, announced today that it will release its financial results for the quarter ending Sept. 30, 2024, on Tuesday, Nov. 12, 2024.

The quarterly results will also be posted on Benson Hill’s investor relations website at https://investors.bensonhill.com.

About Benson Hill

Benson Hill is a seed innovation company that unlocks nature’s genetic diversity in soy quality traits through a combination of its proprietary genetics, its AI-driven CropOS® technology platform, and its Crop Accelerator. Benson Hill collaborates with strategic partners to create value throughout the agribusiness supply chain to meet the demand for better feed, food, and fuel. For more information, visit bensonhill.com or X, formerly known as Twitter, at @bensonhillinc.

Contacts

Investors: Tana Murphy: (314) 579-3184 / investors@bensonhill.com
Media: Christi Dixon: (636) 359-0797 / cdixon@bensonhill.com

Industry:

Benson Hill

NASDAQ:BHIL
Release Summary
Benson Hill will release its financial results for the quarter ending Sept. 30, 2024, on Tuesday, Nov. 12, 2024.
Release Versions
English
$Cashtags
$BHIL
Hashtags
#BHIL
#Earnings
#Financial
#Investors

Contacts

Investors: Tana Murphy: (314) 579-3184 / investors@bensonhill.com
Media: Christi Dixon: (636) 359-0797 / cdixon@bensonhill.com

Social Media Profiles
Benson Hill Twitter
More News From Benson Hill

Confluence Genetics Launches Cas-CLEAR™, a New CRISPR Technology Platform for Cancer Therapy

ST. LOUIS--(BUSINESS WIRE)--Confluence Genetics today announced the launch of Cas-CLEAR™, Collaterally Enhanced Activated Ribonuclease, a new CRISPR technology platform for the treatment of cancers carrying defined genetic signatures, with lead programs in development for hepatocellular carcinoma (HCC). Unlike gene editing CRISPR systems that cut and modify DNA at a single site, Cas-CLEAR uses Cas12a2 nucleases to recognize cancer-specific genetic signatures and trigger broad collateral cleavag...

Confluence Genetics Partners With Ag Partners Cooperative to Increase Commercial Acres of ProVIA™ Soybeans Following Successful Broiler Performance Trials

ST. LOUIS--(BUSINESS WIRE)--Confluence Genetics, LLC. has received positive results from a second collaborative feeding trial with a major poultry integrator, validating the consistent performance benefits of soybean meal derived from the Company's Ultra-High Protein, Low Oligosaccharide (UHP-LO) ProVIA™ soybeans. The 42-day broiler trial replicated results from an initial study with the same integrator, demonstrating that UHP-LO soybean meal can reliably improve broiler performance while reduc...

Confluence Genetics Ultra-High Protein Low Oligosaccharide Soybeans Demonstrate Superior Performance in a Large-Scale Turkey Feeding Trial

ST. LOUIS--(BUSINESS WIRE)--Confluence Genetics, LLC, a leading seed innovation company, today announced positive results from a comprehensive 20-week turkey feeding trial conducted in collaboration with a large poultry integrator. The study validates the commercial advantages of soybean meal made from Confluence Genetics' ProVIA™ Ultra-High Protein, Low Oligosaccharide (UHP-LO) soybeans as a complete replacement for conventional soybean meal in turkey diet formulations. The large-scale trial i...
Back to Newsroom